Subscribe
dna-1
vitstudio / shutterstock.com
17 January 2017Biotechnology

Horizon Discovery expands CRISPR licence

UK-based Horizon Discovery has broadened its gene editing capabilities through the amendment of a pre-existing licence with ERS Genomics to include the full commercial rights for the use of CRISPR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Horizon Discovery expands CRISPR licence with ERS Genomics
5 December 2017   UK-based genomics company Horizon Discovery has expanded its licence coverage for use of the CRISPR gene-editing technology.
Big Pharma
Horizon partners with big pharma company on CRISPR
29 August 2018   UK-based Horizon Discovery has entered into a CRISPR collaboration with an unnamed big pharma company.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Big Pharma
Horizon partners with big pharma company on CRISPR
29 August 2018   UK-based Horizon Discovery has entered into a CRISPR collaboration with an unnamed big pharma company.
Europe
Horizon Discovery expands CRISPR licence with ERS Genomics
5 December 2017   UK-based genomics company Horizon Discovery has expanded its licence coverage for use of the CRISPR gene-editing technology.

More on this story

Big Pharma
Horizon partners with big pharma company on CRISPR
29 August 2018   UK-based Horizon Discovery has entered into a CRISPR collaboration with an unnamed big pharma company.
Europe
Horizon Discovery expands CRISPR licence with ERS Genomics
5 December 2017   UK-based genomics company Horizon Discovery has expanded its licence coverage for use of the CRISPR gene-editing technology.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent